May 18, 2026 08:39AM Scienture reports 449% revenue growth in first quarter 2026

May 7, 2026 08:06AM Scienture secures $11 million in non-dilutive debt financing

May 7, 2026 08:05AM Scienture secures $11 million in non-dilutive debt financing

May 6, 2026 08:05AM SCIENTURE receives third patent for ARBLI losartan suspension through 2041

Apr 6, 2026 08:06AM Scienture reports 216% revenue increase with FDA-approved drug launch

Mar 30, 2026 08:08AM SCIENTURE reports 216% revenue growth in 2025 driven by Arbli launch

Mar 11, 2026 08:06AM Scienture expands naloxone spray access through GPO deals

Feb 24, 2026 07:37AM Maxim Group Starts Scienture Holdings (SCNX) at Buy

Feb 3, 2026 08:06AM SCIENTURE expands access for ARBLI oral losartan suspension

Jan 14, 2026 08:06AM SCIENTURE receives patent for REZENOPY naloxone nasal spray

Dec 22, 2025 08:05AM Scienture expects commercial launch of naloxone spray in Q2 2026

Nov 13, 2025 04:38PM Scienture Holdings (SCNX) Misses Q3 EPS by 19c

Nov 4, 2025 08:05AM Scienture adds Arbli losartan suspension to major health plan formularies

Oct 23, 2025 08:05AM Scienture begins commercial sales of Arbli oral suspension

Oct 13, 2025 08:00AM Wellgistics Health reappoints Prashant Patel as interim CEO

Oct 13, 2025 08:00AM Wellgistics Health Announces Executive Management and Board Changes

Oct 8, 2025 09:03AM SCIENTURE completes debenture conversion with Arena investors

Sep 23, 2025 05:04PM Scienture Holdings enters $9.2 million at-the-market equity offering agreement

Sep 16, 2025 08:05AM SCIENTURE secures rebate deal for liquid losartan drug formulary access

Aug 25, 2025 06:05AM Scienture Holdings (SCNX) Files for 2.1M Share Offering by Selling Stockholders

Jul 24, 2025 05:13PM Scienture Holdings secures $1.2 million in bridge funding

Jul 16, 2025 08:15AM Scienture Holdings regains NASDAQ listing compliance

Jun 17, 2025 08:05AM Scienture Holdings (SCNX) Announces Cancelation of ELOC

May 22, 2025 08:20AM Scienture Holdings (SCNX) CEO steps down

Apr 8, 2025 08:06AM Scienture Holdings (SCNX) to divest legacy subsidiaries for a total consideration of $5M

Apr 3, 2025 08:26AM Scienture Holdings (SCNX) Issues Annual Letter to Shareholders

Mar 25, 2025 08:05AM Scienture Holdings (SCNX) Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health

Jan 30, 2025 06:09AM Scienture Holdings (SCNX) Files for 4.2M Share Offering by Selling Stockholders

Dec 10, 2024 08:06AM Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through

Dec 4, 2024 10:44AM Scienture Holdings (SCNX) Files for 4.3M Share Offering by Selling Stockholders